Acetazolamide for Monge's disease: Efficiency and tolerance of 6-month treatment

American Journal of Respiratory and Critical Care Medicine

Volumn 177, Issue 12, 2008, Pages 1370-1376

  Richalet, Jean Paul ^a,b,f   Rivera Ch, Maria ^c   Maignan, Maxime ^a,d   Privat, Catherine ^c   Pham, Isabelle ^a,e   Macarlupu, Jose Luis ^c   Petitjean, Olivier ^b   León Velarde, Fabiola ^c  

^a UNIVERSITÉ PARIS 13   (France)

^b AVICENNE HOSPITAL   (France)

^c UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e HÔPITAL JEAN VERDIER   (France)

^f AP HP   (France)

Author keywords

Altitude; Chronic mountain sickness; Hypoxia; Pulmonary hypertension

Indexed keywords

ACETAZOLAMIDE; PLACEBO; CARBONATE DEHYDRATASE INHIBITOR;

ADULT; ALTITUDE DISEASE; ARTERIAL OXYGEN TENSION; ARTICLE; BLOOD GAS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIURESIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERANCE; ERYTHROCYTOSIS; FEMALE; HEADACHE; HEART FUNCTION; HEARTBURN; HEMATOCRIT; HUMAN; LUNG ARTERY PRESSURE; LUNG CIRCULATION; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; PARESTHESIA; POLYCYTHEMIA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; ANALYSIS OF VARIANCE; ANOXIA; CHRONIC DISEASE; DRUG EFFECT; ECHOCARDIOGRAPHY; ECHOGRAPHY; HEART OUTPUT; MIDDLE AGED; PERU; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; TRICUSPID VALVE REGURGITATION;

ACETAZOLAMIDE; ALTITUDE SICKNESS; ANALYSIS OF VARIANCE; ANOXIA; CARBONIC ANHYDRASE INHIBITORS; CARDIAC OUTPUT; CHRONIC DISEASE; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PERU; POLYCYTHEMIA; PROSPECTIVE STUDIES; TRICUSPID VALVE INSUFFICIENCY;

EID: 44949157267     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200802-196OC     Document Type: Article

References (30)

1. Monge CC, Arregui A, León-Velarde F. Pathophysiology and epidemiology of chronic mountain sickness. Int J Sports Med 1992;13:S79-S81.
2. León-Velarde F, Maggiorini M, Reeves JT, Aldashev A, Asmus I, Bernardi L, Ge RL, Hackett P, Kobayashi T, Moore LG, et al. Consensus statement on chronic and subacute high altitude diseases. High Alt Med Biol 2005;6:147-157.
3. Penaloza D, Arias-Stella J. The heart and pulmonary circulation at high altitudes: healthy highlanders and chronic mountain sickness. Circulation 2007;115:1132-1146.
4. Antezana A-M, Antezana G, Aparicio O, Noriega I, León-Velarde F, Richalet JP. Pulmonary hypertension in high altitude chronic hypoxia: response to nifedipine. Eur Respir J 1998;12:1181-1185.
5. Richalet JP, Rivera M, Bouchet P, Chirinos E, Onnen I, Petitjean O, Bienvenu A, Lasne F, Moutereau S, León-Velarde F. Acetazolamide: a treatment for chronic mountain sickness. Am J Respir Crit Care Med 2005;172:1427-1433.
6. Höhne C, Krebs MO, Seiferheld M, Boemke W, Kaczmarczyk G, Swenson ER. Acetazolamide prevents hypoxic pulmonary vasoconstriction in conscious dogs. J Appl Physiol 2004;97:515-521.
7. Berg JT, Ramanathan S, Swenson ER. Inhibitors of hypoxic pulmonary vasoconstriction prevent high-altitude pulmonary edema in rats. Wilderness Environ Med 2004;15:32-37.
8. Deem S, Hedges RG, Kerr ME, Swenson ER. Acetazolamide reduces hypoxic pulmonary vasoconstriction in isolated perfused rabbit lungs. Respir Physiol 2000;123:109-119.
9. Teppema LJ, Balanos GM, Steinback CD, Brown AD, Foster GE, Duff HJ, Leigh R, Poulin MJ. Effects of acetazolamide on ventilatory, cerebrovascular, and pulmonary vascular responses to hypoxia. Am J Respir Crit Care Med 2007;175:277-281.
10. Swenson ER. Carbonic anhydrase inhibitors and hypoxic pulmonary vasoconstriction. Respir Physiolo Neurobiol 2006;151:209-216.
11. Höhne C, Pickerodt PA, Francis RC, Boemke W, Swenson ER. Pulmonary vasodilation by acetazolamide during hypoxia is unrelated to carbonic anhydrase inhibition. Am J Physiol Lung Cell Mol Physiol 2007;292:L178-L184.
12. Shimoda LA, Luke T, Sylvester JT, Shih HW, Jain A, Swenson ER. Inhibition of hypoxia-induced calcium responses in pulmonary arterial smooth muscle by acetazolamide is independent of carbonic anhydrase inhibition. Am J Physiol Lung Cell Mol Physiol 2007;292:L1002-L1012.
13. Richalet JP, Maignan M, Pham I, León-Velarde F, Rivera-Ch M, Privat C, Macarlupu JL. Treatment of chronic mountain sickness: new developments. Seventh World Congress of the International Society of Mountain Medicine, Aviemore, Scotland; 3-7 October, 2007.
14. Mezzich JE, Ruipérez MA, Pérez C, Yoon G, Liu J, Mahmud S. The Spanish version of the quality of life index: presentation and validation. J Nerv Ment Dis 2000;188:301-305.
15. Allemann Y, Sartori C, Lepori M, Pierre S, Mélot C, Naeije R, Scherrer U, Maggiorini M. Echocardiographic and invasive measurements of pulmonary artery pressure correlate closely at high altitude. Am J Physiol Heart Circ Physiol 2000;279:H2013-H2016.
16. Kojonazarov BK, Imanov BZ, Amatov TA, Mirrakhimov MM, Naeije R, Wilkins MR, Aldashev AA. Noninvasive and invasive evaluation of pulmonary arterial pressure in highlanders. Eur Respir J 2007;29:352-356.
17. McQuillan BM, Picard MH, Leavitt M, Weyman AE. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation 2001;104:2797-2802.
18. Dabestani A, Mahan G, Gardin JM, Takenaka K, Burn C, Allfie A, Henry WL. Evaluation of pulmonary artery pressure and resistance by pulsed Doppler echography. Am J Cardiol 1987;59:662-668.
19. Abbas AE, Fortuin FD, Schiller NB, Appleton CP, Moreno CA, Lester SJ. A simple method for non invasive estimation of pulmonary vascular resistance. J Am Coll Cardiol 2003;41:1021-1027.
20. León-Velarde F, Richalet JP. Respiratory control in residents at high altitude: physiology and pathophysiology. High Alt Med Biol 2006;7:125-137.
21. Winslow RM, Monge CC. Hypoxia, polycythemia and chronic mountain sickness. Baltimore: Johns Hopkins University Press; 1987. pp.19-30.
22. Monge CC, Lozano R, Whittembury J. Effect of blood-letting on chronic mountain sickness. Nature 1965;207:770.
23. Rivera-Ch M, León-Velarde F, Huicho L. Treatment of chronic mountain sickness: critical reappraisal of an old problem. Respir Physiolo Neurobiol 2007;158:251-265.
24. Kryger M, McCullough RE, Collins D, Scoggin CH, Weil JV, Grover RF. Treatment of excessive polycythemia of high altitude with respiratory stimulant drugs. Am Rev Respir Dis 1978;117:455-464.
25. Vargas M, León-Velarde F, Monge CC, Orozco E, Rey L. Enalapril in the treatment of chronic mountain sickness. Wilderness Environ Med 1996;7:193-194.
26. Plata R, Cornejo A, Arratia C, Anabaya A, Perna A, Dimitrov BD, Remuzzi G, Ruggenenti P; Commission on Global Advancement of Nephrology (COMGAN), Research Subcommittee of the International Society of Nephrology. Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial. Lancet 2002;359:663-666.
27. Deem S, Swenson ER, Alberts MK, Hedges RG, Bishop MJ. Red-blood-cell augmentation of hypoxic pulmonary vasoconstriction. Am J Respir Crit Care Med 1998;157:1181-1186.
28. Weissmann N, Manz D, Buchspies D, Keller S, Mehling T, Voswinckel R, Quanz K, Ghofrani HA, Schermuly RT, Fink L, et al. Congenital erythropoietin over-expression causes "anti-pulmonary hypertensive" structural and functional changes in mice, both in normoxia and hypoxia. Thromb Haemost 2005;94:630-638.
29. Faoro V, Huez S, Giltaire S, Pavelescu A, van Osta A, Moraine JJ, Guénard H, Martinot JB, Naeije R. Effects of acetazolamide on aerobic exercise capacity and pulmonary hemodynamics at high altitudes. J Appl Physiol 2007;103:1161-1165.
30. Stenmarck KR, McMurtry IF. Vascular remodeling versus vasoconstriction in chronic hypoxic pulmonary hypertension: a time for reappraisal? Circ Res 2005;97:95-98.